Benzinga · Mar 2, 2026
ER
NASDAQ · ERNA
Ernexa Therapeutics Inc.
Healthcare · Biotechnology
$2.70
Down-$0.47 (-17.22%)
Updated Oct 6, 2026, 8:19 PM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 11.69M
- P/E ratio
- -0.67
- Dividend yield
- 0.00%
- 52-week range
- $0.18 – $15.88
- Volume
- 21.55K
- Avg. volume
- 3.57M
Price performance · ERNA
ERNA price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
ERNA closed at $2.70 after 20 trading sessions, down 35.56% for the selected period.
- Last close
- $2.70
- Period change
- -35.56%
- Period low
- $2.70
- Period high
- $4.27
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $3.04 | $3.058 | $2.70 | $2.70 | 21.55K |
| Oct 2, 2026 | $3.00 | $3.2798 | $2.90 | $2.96 | 40.81K |
| Oct 1, 2026 | $3.13 | $3.2361 | $2.84 | $2.96 | 35.74K |
| Sep 30, 2026 | $3.24 | $3.47 | $3.16 | $3.20 | 42.64K |
| Sep 29, 2026 | $3.7382 | $3.7382 | $3.0444 | $3.16 | 61.87K |
| Sep 28, 2026 | $3.46 | $3.4999 | $3.20 | $3.47 | 25.79K |
| Sep 25, 2026 | $3.73 | $3.848 | $3.40 | $3.445 | 21.42K |
| Sep 24, 2026 | $3.785 | $3.8213 | $3.61 | $3.62 | 11.53K |
| Sep 23, 2026 | $3.73 | $3.79 | $3.65 | $3.65 | 6.24K |
| Sep 22, 2026 | $3.9599 | $3.9599 | $3.76 | $3.80 | 14.66K |
| Sep 21, 2026 | $4.01 | $4.01 | $3.75 | $3.96 | 13.5K |
| Sep 18, 2026 | $3.79 | $3.885 | $3.79 | $3.83 | 8.28K |
| Sep 17, 2026 | $4.04 | $4.08 | $3.7145 | $3.76 | 33.6K |
| Sep 16, 2026 | $4.01 | $4.155 | $3.84 | $3.91 | 22.56K |
| Sep 15, 2026 | $3.79 | $4.70 | $3.65 | $4.08 | 547.18K |
| Sep 14, 2026 | $4.13 | $4.40 | $4.13 | $4.27 | 16.83K |
| Sep 11, 2026 | $4.05 | $4.4199 | $4.03 | $4.165 | 19.82K |
| Sep 10, 2026 | $3.925 | $4.05 | $3.90 | $4.02 | 11.38K |
| Sep 9, 2026 | $4.20 | $4.23 | $3.97 | $4.02 | 15.65K |
| Sep 8, 2026 | $4.31 | $4.34 | $4.13 | $4.19 | 18.3K |
Latest ERNA news
The latest Smart Investors Daily articles mentioning ERNA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ERNA research
Overview
Company profile and research snapshot.
Company profile
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 7, 2026 | Brookline Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 6, 2026
Ernexa Therapeutics shares are trading lower. The company announced pricing of a $10.5 million public offering.
Benzinga · Feb 6, 2026
Ernexa Therapeutics Prices Registered Public Offering Of 21M Shares And Warrants At $0.50 Per Share And Accompanying Warrant
Ernexa Therapeutics Inc. (NASDAQ:ERNA) ("Ernexa" or the "Company"), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the pricing of a
globenewswire.com · Dec 3, 2025
Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting
CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that data from its novel cell therapy platform will be shared in an oral presentation at the 67 th ASH Annual Meeting , being held December 6-9, 2025 in Orlando, FL.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
